96566-25-5

96566-25-5 structure

Name: Ablukast
Chemical Name: 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid
CAS Number: 96566-25-5
Molecular Formula: C₂₈H₃₄O₈
Molecular Weight: 498.56500
Catalog: Signaling Pathways GPCR/G Protein Leukotriene Receptor
Create Date: 2018-02-20 08:00:00
Modify Date: 2024-01-03 10:41:55
Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3].

Name	6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid
Synonyms	rac-6-acetyl-7-<<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl>oxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid Ablukast 4-dihydro-2H-1-benzopyran-2-carboxylic acid Ablukastum 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 6-acetyl-7-<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid UNII-000TKM5BBQ Ro-23-3544 Ablukast (USAN/INN) Ablukastum [INN-Latin] 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3

Description	Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Leukotriene Receptor Research Areas >> Inflammation/Immunology
Target	LTD4
In Vitro	Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2].
In Vivo	Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2]. Animal Model: Female BALB/c mice[2] Dosage: Concentrations of 0.1 , 0.5 , 1.0 and 5.0 % of Ablukast Administration: Applied to one of the pretreated ears 1 h after elicitation and at 24 h intervals on the following 4 days; three times daily Result: Effectively reduced DNFB-induced ear swelling.
References	[1]. M O'Donnell, et al. Pharmacological profile of Ro 23-3544, a new aerosol active leukotriene receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:512-8. [2]. T Rosenbach, et al. Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis. Br J Dermatol. 1988 Jan;118(1):1-6. [3]. Hans-Michael Eggenweiler, et al. Pyrrolopyrimidines as phosphodiesterase VII inhibitors. US7498334B2.

Density	1.219g/cm3
Boiling Point	730.8ºC at 760mmHg
Molecular Formula	C₂₈H₃₄O₈
Molecular Weight	498.56500
Flash Point	240.9ºC
Exact Mass	498.22500
PSA	119.36000
LogP	5.15620
Index of Refraction	1.567

Precursor 9
120329-95-5 122443-78-1 23866-72-0 111-24-0
89-84-9 40786-69-4 96566-14-2 38987-00-7
40815-74-5
DownStream 0

96566-25-5	96565-55-8
1158522-08-7	1416439-97-8
940364-43-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1